Therapy effects of wogonin on ovarian cancer cells

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Ruibin, Jiang ^a   Bo, Jin ^b   Danying, Wan ^a   Chihong, Zhu ^a   Jianguo, Feng ^a,c   Linhui, Gu ^a,c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c Key Laboratory Diagnosis and Treatment Technology on Thoracic Oncology   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLAVANONE DERIVATIVE; TUMOR PROTEIN; WOGONIN;

BIOSYNTHESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; FEMALE; FLAVANONES; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RESTING PHASE, CELL CYCLE;

EID: 85040975578     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/9381513     Document Type: Article

References (45)

1. S. Chen, M. Cooper, M. Jones et al., "Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells," Cell Biology and Toxicology, vol. 27, no. 2, pp. 133-147, 2011.
2. J. Spiliotis, E. Halkia, E. Lianos et al., "Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study," Annals of Surgical Oncology, vol. 22, no. 5, pp. 1570-1575, 2015.
3. A. L. Shafrir, M. S. Rice, M. Gupta et al., "The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status," Gynecologic Oncology, vol. 143, no. 3, pp. 628-635, 2016.
4. E. Dudko, T. Bogush, S. Kolomiytsev et al., "Quantitative analysis of estrogen receptors alpha and beta expression in ovarian cancer patients by flow cytometry," European Journal of Cancer, vol. 61, p. S71, 2016.
5. 18F-fluoro-17β-estradiol PET/CT," Journal of Nuclear Medicine, vol. 56, no. 1, pp. 50-55, 2015.
6. M.-A. Park, K.-A. Hwang, H.-R. Lee, B.-R. Yi, E.-B. Jeung, and K.-C. Choi, "Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models," Toxicology, vol. 305, pp. 41-48, 2013.
7. J. Lu, Y. Xu, X. Wei, Z. Zhao, J. Xue, and P. Liu, "Emodin inhibits the epithelial to mesenchymal transition of epithelial ovarian cancer cells via ILK/GSK-3β/Slug signaling pathway," Bio Med Research International, vol. 2016, Article ID 6253280, 16 pages, 2016.
8. K. K.-L. Chan, T. H.-Y. Leung, D. W. Chan et al., "Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer," Journal of Endocrinology, vol. 221, no. 2, pp. 325-336, 2014.
9. J. Fujimoto, R. Hirose, H. Sakaguchi, and T. Tamaya, "Clinical significance of expression of estrogen receptor α and β mRMAs in ovarian cancers," Oncology, vol. 58, no. 4, pp. 334-341, 2000.
10. J. Li, Q. Zhuang, X. Lan, G. Zeng, X. Jiang, and Z. Huang, "PES1 differentially regulates the expression of ERα and ERβ in ovarian cancer," IUBMB Life, vol. 65, no. 12, pp. 1017-1025, 2013.
11. C.-H. Chien, F.-F. Wang, and T. C. Hamilton, "Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells," Molecular and Cellular Endocrinology, vol. 99, no. 1, pp. 11-19, 1994.
12. M. Galtier, J. M. Nores, and J. M. Remy, "Beta blockade prophylaxis of accessory pathway catecholamine sensitive circus movement tachycardia," The European journal of medicine, vol. 1, no. 2, pp. 125-126, 1992.
13. J.-H. Choi, K.-T. Lee, and P. C. K. Leung, "Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth," Carcinogenesis, vol. 32, no. 4, pp. 589-596, 2011.
14. A. Scafonas, A. A. Reszka, D. B. Kimmel et al., "Agonist-like SERM effects on ERα-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus," The Journal of Steroid Biochemistry and Molecular Biology, vol. 110, no. 3-5, pp. 197-206, 2008.
15. Sharma SFCMWTSYA, "Determining the role of somatic ERα mutations in acquired hormone (or SERM) resistance," Cancer Research, vol. 75, no. 9, article 4, 2015.
16. K. Ohta, T. Ogawa, A. Kaise, and Y. Endo, "Synthesis and biological evaluation of novel m-carborane-containing estrogen receptor partial agonists as SERM candidates," Bioorganic and Medicinal Chemistry Letters, vol. 25, no. 16, pp. 3213-3216, 2015.
17. J. I. Dower, J. M. Geleijnse, L. Gijsbers, P. L. Zock, D. Kromhout, and P. C.H. Hollman, "Effectsof the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial," American Journal of Clinical Nutrition, vol. 101, no. 5, pp. 914-921, 2015.
18. S. D. S. Banjarnahor and N. Artanti, "Antioxidant properties of flavonoids," Medical Journal of Indonesia, vol. 23, no. 4, pp. 239-244, 2014.
19. X. Shi, D. Liu, J. Zhang et al., "Extraction and purification of total flavonoids frompine needles of Cedrus deodara contribute to anti-tumor in vitro," BMC Complementary and Alternative Medicine, vol. 16, article no. 245, 2016.
20. L.-G. Chen, L.-Y. Hung, K.-W. Tsai et al., "Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells," Molecular Nutrition and Food Research, vol. 52, no. 11, pp. 1349-1357, 2008.
21. S. Chen, L. Zhang, G. Yan et al., "Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker in patients with ovarian cancer: a meta-analysis," Bio Med Research International, vol. 2017, pp. 1-7, 2017.
22. F. Chen, R. Wu, Z. Zhu et al., "Wogonin protects rat dorsal root ganglion neurons against tunicamycin-induced ER stress through the PERK-eIF2α-ATF4 signaling pathway," Journal of Molecular Neuroscience, vol. 55, no. 4, pp. 995-1005, 2015.
23. D. Wozniak, A. Drys, and A. Matkowski, "Antiradical and antioxidant activity of flavones from Scutellariae baicalensis radix," Natural Product Research, vol. 29, no. 16, pp. 1567-1570, 2015.
24. D.-H. Lee, C. Kim, L. Zhang, and Y. J. Lee, "Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells," Biochemical Pharmacology, vol. 75, no. 10, pp. 2020-2033, 2008.
25. D.-H. Lee, T. H. Lee, C. H. Jung, and Y.-H. Kim, "Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells," Cellular Signalling, vol. 24, no. 11, pp. 2216-2225, 2012.
26. L. Yang, H.-W. Zhang, R. Hu et al., "Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells," Biochemistry and Cell Biology, vol. 87, no. 6, pp. 933-942, 2009.
27. N. Lu, Y. Gao, Y. Ling et al., "Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2," Life Sciences, vol. 82, no. 17-18, pp. 956-963, 2008.
28. X. Song, Y. Zhou, M. Zhou et al., "Wogonin influences vascular permeability via Wnt/β-catenin pathway," Molecular Carcinogenesis, vol. 54, no. 7, pp. 501-512, 2015.
29. J. Q. Yu, H. B. Liu, D. Z. Tian, Y.W. Liu, J. C. Lei, and G. L. Zou, "Changes in mitochondrial membrane potential and reactive oxygen species during wogonin-induced cell death in human hepatoma cells," Hepatology Research, vol. 37, no. 1, pp. 68-76, 2007.
30. J. Feng, S. Zhang, K. Wu et al., "Combined effects of suberoylanilide hydroxamic acid and cisplatin on radiation sensitivity and cancer cell invasion in non-small cell lung cancer," Molecular Cancer Therapeutics, vol. 15, no. 5, pp. 842-853, 2016.
31. G. Liu, G. Guan, and J. Fang, " Macleaya cordata extract decreased diarrhea score and enhanced intestinal barrier function in growing piglets," Bio Med Research International, vol. 2016, Article ID 1069585, 7 pages, 2016.
32. G. Liu, S. Chen, J. Zhong, K. Teng, and Y. Yin, "Crosstalk between tryptophan metabolism and cardiovascular disease, mechanisms, and therapeutic implications," Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 1602074, 5 pages, 2017.
33. W. L. W. Hsiao and L. Liu, "The role of traditional Chinese herbal medicines in cancer therapy-from TCM theory to mechanistic insights," Planta Medica, vol. 76, no. 11, pp. 1118-1131, 2010.
34. C. Hu, M. Xu, R. Qin, W. Chen, and X. Xu, "Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway," Oncology Reports, vol. 33, no. 6, pp. 3146-3154, 2015.
35. W. Wang, Q. Guo, Q. You et al., "Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line SMMC-7721," Anti-Cancer Drugs, vol. 17, no. 7, pp. 797-805, 2006.
36. K. F. Huang, G. D. Zhang, Y. Q. Huang, and Y. Diao, "Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway," International Immunopharmacology, vol. 12, no. 2, pp. 334-341, 2012.
37. S. H. Erdman, H. D. Wu, L. J. Hixson, D. J. Ahnen, and E. W. Gerner, "Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats," Molecular Carcinogenesis, vol. 19, no. 2, pp. 137-144, 1997.
38. F. Kruiswijk, C. F. Labuschagne, and K. H. Vousden, "P53 in survival, death and metabolic health: a lifeguard with a licence to kill," Nature Reviews Molecular Cell Biology, vol. 16, no. 7, pp. 393-405, 2015.
39. V. Kirkin, S. Joos, and M. Zörnig, "The role of Bcl-2 family members in tumorigenesis," Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, vol. 1644, no. 2-3, pp. 229-249, 2004.
40. M. K. Manion and D. M. Hockenbery, "Targeting BCL-2-related proteins in cancer therapy," Cancer Biology & Therapy, vol. 2, supplement 1, no. 4, pp. S105-S114, 2003.
41. F. Acconcia, P. Totta, S. Ogawa et al., "Survival versus apoptotic 17β-estradiol effect: role of ERα and ERβ activated nongenomic signaling," Journal of Cellular Physiology, vol. 203, no. 1, pp. 193-201, 2005.
42. L. Mauro, M. Pellegrino, F. Giordano et al., "Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells," FASEB Journal, vol. 29, no. 5, pp. 2150-2160, 2015.
43. E. Burandt, M. Grünert, A. Lebeau et al., "Cyclin D1 gene amplification is highly homogeneous in breast cancer," Breast Cancer, vol. 23, no. 1, pp. 111-119, 2016.
44. X. Li, X. Gong, J. Chen, J. Zhang, J. Sun, and M. Guo, "MiR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2," Biochemical and Biophysical Research Communications, vol. 460, no. 3, pp. 670-677, 2015.
45. Y.-F. Tao, N.-N. Wang, L.-X. Xu et al., "Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells," Cancer Cell International, vol. 17, no. 1, article no. 35, 2017.